AstraZeneca Reports Positive Results from Imfinzi Combo Study in Bladder Cancer
AstraZeneca announced interim results from the Phase 3 VOLGA trial, showing that its Imfinzi (durvalumab) and neoadjuvant enfortumab vedotin combination significantly improved event-free survival and overall survival in muscle-invasive bladder cancer patients. The study compared this regimen against standard cisplatin-based chemotherapy.